We can reimburse for travel and inconvenience
If you are eligible to take part in our ethically approved trials, you will be helping in the research for new medicines.
Download flyer [PDF 256KB] for more information.
The big question is, would taking blood pressure medication in the evening be better (or worse) than taking it in the morning in preventing strokes and heart attacks? The TIME study will try to answer this question
We are currently recruiting patients with high cholesterol and a history of heart disease, kidney disease or diabetes for a study of an investigational medication. Find out more about the SPIRE Study.
We are currently recruiting patients for a clinical research study looking at a concentrate of omega-3 fatty acids to see whether it can help to decrease the risk of serious heart problems in people diagnosed as having a high risk of heart disease.
Watch our videos to learn more about what's involved and how you can participate.
Join our trial of “life changing” one-hour treatment to lower blood pressure. Local people suffering from uncontrolled high blood pressure are being invited to take up an exciting new treatment using ultrasound-based energy, being trialled for the first time in London at St Bartholomew’s Hospital this summer.
The one-hour treatment is an exciting and innovative opportunity for the estimated 4%  of adults in London living with resistant hypertension - a severe form of high blood pressure that cannot be controlled with drug therapy, putting them at constant risk of suffering a stroke or severe heart problems.
The treatment is the subject of a randomised clinical trial known as WAVE IV. In previous trials of the therapy, three-quarters of treated patients experienced a meaningful reduction in their blood pressure following the one-time, one-hour therapy.
Now, people in east London are being given the chance to sign up to the randomised trial being run by Queen Mary University of London and Barts Health NHS Trust.
Patients may be eligible to participate in the WAVE IV clinical study if:
• They are aged between 18 years of age and 90 years of age.
• Their systolic blood pressure (top number) is greater than 160 mmHg.
• They are currently taking three or more prescription medications for high blood pressure.
People who wish to find out more and assess their suitability for the trial can contact Anne Zak at the William Harvey Heart Centre Clinical Trials Unit on 0207 882 5657.
The CARMELINA Study is a Phase 4 clinical trial. The purpose of the CARMELINA Study is to look at the impact of linagliptin on the long-term occurrence of selected complications of cardiovascular disease (e.g. stroke or heart attack), as compared to placebo, in people with type 2 diabetes mellitus receiving standard of care.
Find out more about the CARMELINA study
The Credence study is looking at an investigational medication versus placebo to see if it can slow down the progression of kidney disease in patients with Type 2 Diabetes.
Find out more about the Credence Study (PDF)
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Alirocumab on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome.
Find out more about the Odyssey study (PDF).
We are currently recruiting patients for a clinical research study looking at an investigational medication for people with severe COPD that is already approved at a particular dose in more than 60 countries. This study looks at how effective the investigational medication is when it is taken at different doses. The study medication is a tablet taken once a day in addition to your existing COPD treatments. For further details click.
Find out more about the Optimize study (PDF).
The Tommorrow study is researching a new investigational test to see if it can help identify individuals who are at higher risk of developing memory problems due to Alzheimer’s disease in the next 5 years and testing a new investigational treatment to see if it can delay the memory problems due to Alzheimer’s disease. This research study is currently recruiting healthy older participants. Find out more about being part of this new research effort.
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When Evolocumab (AMG 145) is Used in Combination With Statin Therapy In Patients With Clinically Evident Cardiovascular Disease.